Stock PBH PRESTIGE CONSUMER HEALTHCARE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Prestige Consumer Healthcare Inc.

Equities

PBH

US74112D1019

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 16:00:01 2024-04-26 EDT 		5-day change 1st Jan Change
70.47 USD +0.47% Intraday chart for Prestige Consumer Healthcare Inc. +1.15% +15.11%
02-16 Prestige Consumer Healthcare Insider Sold Shares Worth $1,766,665, According to a Recent SEC Filing MT
02-16 Prestige Consumer Healthcare Insider Sold Shares Worth $2,051,874, According to a Recent SEC Filing MT

Valuation

Fiscal Period: März 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,549 1,844 2,198 2,658 3,112 3,499 - -
Enterprise Value (EV) 1 1,549 1,844 2,198 2,658 3,112 4,569 4,325 4,078
P/E ratio -43.3 x 13.2 x 13.6 x 13.1 x -38 x 16.3 x 15.2 x 14.5 x
Yield - - - - - - - -
Capitalization / Revenue 1.59 x 1.91 x 2.33 x 2.45 x 2.76 x 3.08 x 3.01 x 2.94 x
EV / Revenue 1.59 x 1.91 x 2.33 x 2.45 x 2.76 x 4.02 x 3.72 x 3.43 x
EV / EBITDA 4.67 x 5.62 x 6.68 x 7.23 x 8.23 x 11.9 x 11 x 10.1 x
EV / FCF 8.66 x 9.1 x 10.3 x 10.6 x 14 x 17 x 15.9 x 14.3 x
FCF Yield 11.5% 11% 9.71% 9.42% 7.13% 5.87% 6.3% 7.02%
Price to Book 1.41 x 1.59 x 1.62 x 1.69 x 2.15 x 2.16 x 1.88 x -
Nbr of stocks (in thousands) 51,798 50,266 49,865 50,199 49,688 49,649 - -
Reference price 2 29.91 36.68 44.08 52.94 62.63 70.47 70.47 70.47
Announcement Date 19-05-09 20-05-07 21-05-06 22-05-05 23-05-04 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 975.8 963 943.4 1,087 1,128 1,136 1,162 1,190
EBITDA 1 331.4 328.1 328.9 367.7 378.1 383.2 393.6 404
EBIT 1 299.6 299.1 298.8 326.7 347.8 350.9 360.5 369.4
Operating Margin 30.71% 31.06% 31.67% 30.06% 30.84% 30.9% 31.03% 31.04%
Earnings before Tax (EBT) 1 -38.06 191.2 204.1 262.5 -93.92 283.5 304 315.7
Net income 1 -35.8 142.3 164.7 205.4 -82.31 216.7 230.8 239.1
Net margin -3.67% 14.77% 17.46% 18.9% -7.3% 19.08% 19.87% 20.09%
EPS 2 -0.6900 2.780 3.250 4.040 -1.650 4.331 4.627 4.855
Free Cash Flow 1 178.8 202.6 213.4 250.3 221.9 268.1 272.4 286.1
FCF margin 18.32% 21.03% 22.62% 23.03% 19.68% 23.61% 23.45% 24.03%
FCF Conversion (EBITDA) 53.95% 61.74% 64.87% 68.08% 58.7% 69.97% 69.2% 70.82%
FCF Conversion (Net income) - 142.37% 129.56% 121.86% - 123.7% 118.01% 119.63%
Dividend per Share - - - - - - - -
Announcement Date 19-05-09 20-05-07 21-05-06 22-05-05 23-05-04 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 276.2 274.5 266.9 277.1 289.3 275.5 285.9 279.3 286.3 282.7 287.4 285.5 293.1 289.4 294.7
EBITDA 1 92.72 90.47 85.42 94.57 91.82 94.16 97.53 93.98 95.66 93.8 98.55 97.19 98.81 97.38 102.1
EBIT 1 84.76 82.42 76.94 86.19 83.57 86.03 89.22 85.19 88.25 86.83 90.68 88.17 90.28 89.58 93.37
Operating Margin 30.68% 30.03% 28.82% 31.11% 28.89% 31.23% 31.21% 30.5% 30.82% 30.71% 31.56% 30.88% 30.8% 30.96% 31.69%
Earnings before Tax (EBT) 1 59.63 65.49 60.96 70.9 66.59 68.12 -299.5 68.71 70.42 69.58 74.75 73.46 75.82 76 80.35
Net income 1 45.32 50.22 52.09 55.27 51.02 51.95 -240.6 53.28 53.56 53.05 56.87 55.91 57.7 57.81 61.16
Net margin 16.41% 18.3% 19.51% 19.95% 17.64% 18.86% -84.15% 19.07% 18.71% 18.76% 19.79% 19.58% 19.69% 19.98% 20.76%
EPS 2 0.8900 0.9900 1.020 1.090 1.020 1.040 -4.830 1.060 1.070 1.060 1.140 1.116 1.154 1.156 1.226
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 21-11-04 22-02-03 22-05-05 22-08-04 22-11-03 23-02-02 23-05-04 23-08-03 23-11-02 24-02-08 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - 1,071 826 579
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) - - - - - 2.794 x 2.099 x 1.434 x
Free Cash Flow 1 179 203 213 250 222 268 272 286
ROE (net income / shareholders' equity) 12.8% 13.4% 13% 14.1% 14% 13.6% 12.7% 12.2%
ROA (Net income/ Total Assets) - - - - - 6.3% 6.2% 5.9%
Assets 1 - - - - - 3,440 3,723 4,053
Book Value Per Share 2 21.20 23.10 27.20 31.40 29.10 32.60 37.40 -
Cash Flow per Share 2 - - - - - 5.420 5.130 5.370
Capex 1 10.5 14.6 22.2 9.64 7.78 10.1 12 12.3
Capex / Sales 1.07% 1.51% 2.36% 0.89% 0.69% 0.89% 1.04% 1.03%
Announcement Date 19-05-09 20-05-07 21-05-06 22-05-05 23-05-04 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Prestige Consumer Healthcare Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
70.47 USD
Average target price
74.33 USD
Spread / Average Target
+5.48%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PRESTIGE CONSUMER HEALTHCARE INC. Stock Prestige Consumer Healthcare Inc.
+15.11% 3.5B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PBH Stock
  4. Financials Prestige Consumer Healthcare Inc.